Pretreatment Vitamin D deficiency is associated with impaired progression-free and overall survival in hodgkin lymphoma (2019) Borchmann S, Cirillo M, Goergen H, Meder L, Sasse S, Kreissl S, Broeckelmann PJ, et al. Journal article Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT) (2018) Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, et al. Journal article Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study (2018) Fasching P, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, et al. Journal article Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018) Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al. Journal article Eosinophil-cationic protein: A novel liquid prognostic biomarker in melanoma (2018) Moreira A, Krueckel A, Schuler G, Heinzerling L Conference contribution Can checkpoint inhibitor therapy improve response to chemotherapy? (2017) Boßerhoff AK, Schuler G, Heinzerling L, Schilling B, Haferrkamp S, Kirchberger M Conference contribution, Conference Contribution CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial (2017) Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, et al. Journal article Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers (2016) Schmidt MK, Hogervorst F, Van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers H, et al. Journal article Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma (2016) Crump M, Leppa S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, et al. Journal article